Skip to main content
Fig. 9 | Stem Cell Research & Therapy

Fig. 9

From: Oct4-dependent FoxC1 activation improves the survival and neovascularization of mesenchymal stem cells under myocardial ischemia

Fig. 9

Oct4 enhances FoxC1-mediated MEndoT after MSC therapy. A Representative fluorescence microscopy images of tissue sections showing the retention of EGFP labeling MSCs at the injection site 30 days after transplantation. Scale bar: 100 μm. E Quantitative data showing the retention of EGFP+ MSCs in the ischemic hearts. B Representative phenotype of gated EGFP+ cells evaluated by FACS. F Quantitative analysis of the percentages of EGFP-positive cells (EGFP+) relative to the whole ventricular cell population in the ischemic hearts after 30 days of transplantation. C, G Endothelial cell immunostaining in EGFP-labeled MSCs (C, arrowheads) and quantitation of endothelial cell expression (G). Scale bar: 50 μm. D, H Vascular density images assessed by factor VIII immunostaining (D) and statistical analysis of blood vessels (H) in various groups 30 days after cell therapy, respectively. Scale bar: 100 μm. (I) Quantitation of infarct size. J, K, L The changes of LVFS (J), LVEDD (K), and LVEDV (L) prior to and 30 days after cell therapy. All graphs show means ± SEM. p < 0.05: in the ischemic hearts without FoxC1 transfection, *versus MSC therapy alone, †versus Transplantation of adOct4 transfected MSCs, ‡versus Transplantation of siOct4 transfected MSCs; in the adFoxC1 hearts, §versus MSC therapy alone, ||versus Transplantation of adOct4 transfected MSCs (n = 10 per group). Welch ANOVA analyses were performed in E–I and K, and one-way ANOVA analysis was used in J and L

Back to article page